High-Purity Preparation of HSV-2 Vaccine Candidate ACAM529 Is Immunogenic and Efficacious In Vivo

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Mundle, Sophia T ^a   Hernandez, Hector ^a   Hamberger, John ^a   Catalan, John ^a   Zhou, Changhong ^a   Stegalkina, Svetlana ^a   Tiffany, Andrea ^a   Kleanthous, Harry ^a   Delagrave, Simon ^a   Anderson, Stephen F ^a  

^a SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACAM 529; HERPES VACCINE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE CHROMATOGRAPHY; ANTIBODY RESPONSE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG PURIFICATION; FEMALE; GENITAL HERPES; GOOD MANUFACTURING PRACTICE; HERPES SIMPLEX VIRUS 2; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; MOLECULAR CLONING; MOUSE; NONHUMAN; ULTRACENTRIFUGATION; ULTRAFILTRATION; VACCINATION; VACCINE PRODUCTION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY, ION EXCHANGE; DEXTRAN SULFATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; ULTRACENTRIFUGATION; VERO CELLS; VIRAL VACCINES;

EID: 84874498832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057224     Document Type: Article

References (46)

1. Mertz KJ, Trees D, Levine WC, Lewis JS, Litchfield B, et al. (1998) Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 178: 1795-1798.
2. Mertz KJ, Weiss JB, Webb RM, Levine WC, Lewis JS, et al. (1998) An investigation of genital ulcers in Jackson, Mississippi, with use of a multiplex polymerase chain reaction assay: high prevalence of chancroid and human immunodeficiency virus infection. J Infect Dis 178: 1060-1066.
3. Paz-Bailey G, Rahman M, Chen C, Ballard R, Moffat HJ, et al. (2005) Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis 41: 1304-1312.
4. Pena KC, Adelson ME, Mordechai E, Blaho JA, (2010) Genital herpes simplex virus type 1 in women: detection in cervicovaginal specimens from gynecological practices in the United States. J Clin Microbiol 48: 150-153.
5. Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, et al. (2006) The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis 194Suppl 1: S11-18.
6. Looker KJ, Garnett GP, Schmid GP (2008) An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86: 805-812, A.
7. Fisman DN, Lipsitch M, Hook EW 3rd, Goldie SJ (2002) Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex Transm Dis 29: 608-622.
8. Johnston C, Koelle DM, Wald A, (2011) HSV-2: in pursuit of a vaccine. J Clin Invest 121: 4600-4609.
9. Kutinova L, Benda R, Kalos Z, Dbaly V, Votruba T, et al. (1988) Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine 6: 223-228.
10. Skinner GR, Turyk ME, Benson CA, Wilbanks GD, Heseltine P, et al. (1997) The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol 186: 31-36.
11. Casanova G, Cancela R, Alonzo L, Benuto R, Magana Mdel C, et al. (2002) A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 70: 235-239.
12. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, et al. (2006) A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24: 914-920.
13. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, et al. (2012) Live Attenuated Herpes Simplex Virus Type 2 Glycoprotein E Deletion Mutant as a Vaccine Candidate Defective in Neuronal Spread. J Virol.
14. Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, et al. (2005) Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 40: 1271-1281.
15. Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, et al. (1995) A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med 122: 889-898.
16. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652-1661.
17. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, et al. (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343: 1460-1463.
18. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, et al. (1997) Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 176: 1129-1134.
19. Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, et al. (2008) Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 15: 1638-1643.
20. Koelle DM, Magaret A, McClurkan CL, Remington ML, Warren T, et al. (2008) Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects. Clin Vaccine Immunol 15: 773-782.
21. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34-43.
22. Watson-Jones D, Weiss HA, Rusizoka M, Baisley K, Mugeye K, et al. (2007) Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. J Acquir Immune Defic Syndr 46: 631-642.
23. Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, et al. (2012) Immunogenicity and Efficacy of Intramuscular Replication-Defective and Subunit Vaccines against Herpes Simplex Virus Type 2 in the Mouse Genital Model. PLoS One 7: e46714.
24. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM, (2000) Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 74: 7963-7971.
25. Da Costa XJ, Jones CA, Knipe DM, (1999) Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A 96: 6994-6998.
26. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, et al. (2005) Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 79: 410-418.
27. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, et al. (2009) Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200: 1088-1095.
28. Arens M, Swierkosz E, Dilworth V, (1988) Effects of sonication and centrifugation of clinical specimens on the recovery of herpes simplex virus. Diagn Microbiol Infect Dis 11: 137-143.
29. Lotfian P, Levy MS, Coffin RS, Fearn T, Ayazi-Shamlou P, (2003) Impact of process conditions on the centrifugal recovery of a disabled herpes simplex virus. Biotechnol Prog 19: 209-215.
30. Goins WF, Krisky DM, Wechuck JB, Huang S, Glorioso JC, (2008) Construction and production of recombinant herpes simplex virus vectors. Methods Mol Biol 433: 97-113.
31. Sathananthan B, Rodahl E, Flatmark T, Langeland N, Haarr L, (1997) Purification of herpes simplex virus type 1 by density gradient centrifugation and estimation of the sedimentation coefficient of the virion. APMIS 105: 238-246.
32. Sia KC, Wang GY, Ho IA, Khor HY, Miao L, et al. (2007) Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration. J Virol Methods 139: 166-174.
33. Szilagyi JF, Cunningham C, (1991) Identification and characterization of a novel non-infectious herpes simplex virus-related particle. J Gen Virol 72 (Pt 3): 661-668.
34. Knop DR, Harrell H, (2007) Bioreactor production of recombinant herpes simplex virus vectors. Biotechnol Prog 23: 715-721.
35. Jiang C, Ataai M, Ozuer A, Krisky D, Wechuck J, et al. (2006) Inactivation of herpes simplex type 1 gene vector on immobilized metal affinity chromatography: oxidative damage by hydroxyl free radicals and its prevention. Biotechnol Bioeng 95: 48-57.
36. Jiang C, Wechuck JB, Goins WF, Krisky DM, Wolfe D, et al. (2004) Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol 78: 8994-9006.
37. Wolf MW, Reichl U, (2011) Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 10: 1451-1475.
38. Nahmias AJ, Kibrick S, (1964) Inhibitory effect of heparin on herpes simplex virus. J Bacteriol 87: 1060-1066.
39. Baba M, Snoeck R, Pauwels R, de Clercq E, (1988) Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 32: 1742-1745.
40. Neyts J, Reymen D, Letourneur D, Jozefonvicz J, Schols D, et al. (1995) Differential antiviral activity of derivatized dextrans. Biochem Pharmacol 50: 743-751.
41. Piret J, Lamontagne J, Bestman-Smith J, Roy S, Gourde P, et al. (2000) In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. J Clin Microbiol 38: 110-119.
42. Banfield BW, Leduc Y, Esford L, Visalli RJ, Brandt CR, et al. (1995) Evidence for an interaction of herpes simplex virus with chondroitin sulfate proteoglycans during infection. Virology 208: 531-539.
43. Dyer AP, Banfield BW, Martindale D, Spannier DM, Tufaro F, (1997) Dextran sulfate can act as an artificial receptor to mediate a type-specific herpes simplex virus infection via glycoprotein B. J Virol. 71: 191-198.
44. Yeung SN, Bockhold K, Tufaro F, (1999) Efficient infection of mature skeletal muscle with herpes simplex virus vectors by using dextran sulfate as a co-receptor. Gene Ther 6: 1536-1544.
45. O'Keeffe R, Johnston MD, Slater NK, (1998) The primary production of an infectious recombinant Herpes Simplex Virus vaccine. Biotechnol Bioeng 57: 262-271.
46. O'Keeffe RS, Johnston MD, Slater NK, (1999) The affinity adsorptive recovery of an infectious herpes simplex virus vaccine. Biotechnol Bioeng 62: 537-545.